1-17 of 17
Henk M.W. Verheul
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol

Available to Purchase
Karlijn Verkerk, Tijmen J.W.T. van der Wel, Laurien J. Zeverijn, Birgit S. Geurts, Ilse A.C. Spiekman, Gijs F. de Wit, Paul Roepman, Anne M.L. Jansen, Vincent van der Noort, Egbert F. Smit, Ann Hoeben, Lizza E.L. Hendriks, Michel M. van den Heuvel, Berber Piet, Gerarda J.M. Herder, Sayed M.S. Hashemi, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest, Adrianus J. de Langen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5323–5332.
https://doi.org/10.1158/1078-0432.CCR-24-1925
Published: 02 December 2024
View articletitled, Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Open the PDF for Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

Available to Purchase
Laurien J. Zeverijn, Birgit S. Geurts, Thomas W. Battaglia, Jade M. van Berge Henegouwen, Gijs F. de Wit, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Paul Roepman, Wendy W.J. de Leng, Anne M.L. Jansen, Myriam Chalabi, Carla M.L. van Herpen, Lot A. Devriese, Frans L.G. Erdkamp, Mariette Labots, Maja J.A. de Jonge, Emile D. Kerver, Adriaan D. Bins, Lindsay V.M. Leek, Jessica C.L. Notohardjo, Alfonsus J.M. van den Eertwegh, Lodewyk F.A. Wessels, Henk M.W. Verheul, Hans Gelderblom, Joris van de Haar, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4339–4351.
https://doi.org/10.1158/1078-0432.CCR-24-0480
Published: 01 October 2024
View articletitled, The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Open the PDF for The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol

Available to Purchase
Jade M. van Berge Henegouwen, Laurien J. Zeverijn, Birgit S. Geurts, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Alwin D.R. Huitema, Filip Y.F. de Vos, Katrien Grünberg, Haiko J. Bloemendal, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3937–3943.
https://doi.org/10.1158/1078-0432.CCR-23-3917
Published: 03 September 2024
View articletitled, Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Open the PDF for Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol

Available to Purchase
Birgit S. Geurts, Laurien J. Zeverijn, Lindsay V.M. Leek, Jade M. van Berge Henegouwen, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Joris van de Haar, Annemiek van Ommen-Nijhof, Marleen Kok, Paul Roepman, Anne M.L. Jansen, Wendy W.J. de Leng, Maja J.A. de Jonge, Ann Hoeben, Carla M.L. van Herpen, Hans M. Westgeest, Lodewyk F.A. Wessels, Henk M.W. Verheul, Hans Gelderblom, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3735–3746.
https://doi.org/10.1158/1078-0432.CCR-24-0011
Published: 03 September 2024
View articletitled, Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Open the PDF for Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Open Access
Myra E. van Linde, Mariette Labots, Cyrillo G. Brahm, Koos E. Hovinga, Philip C. De Witt Hamer, Richard J. Honeywell, Richard de Goeij-de Haas, Alex A. Henneman, Jaco C. Knol, Godefridus J. Peters, Henk Dekker, Sander R. Piersma, Thang V. Pham, William P. Vandertop, Connie R. Jiménez, Henk M.W. Verheul
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1595–1602.
https://doi.org/10.1158/1078-0432.CCR-21-1933
Published: 14 April 2022
View articletitled, Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
Open the PDF for Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Open Access
Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne L. van der Velden, Joris van de Haar, Paul Roepman, Wendy J. de Leng, Anne M.L. Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D.R. Huitema, Eelke H. Gort, Jan Willem B. de Groot, Emile D. Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens V. Beerepoot, Mathijs P. Hendriks, Egbert F. Smit, Winette T.A. van der Graaf, Carla M.L. van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P. Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1402–1411.
https://doi.org/10.1158/1078-0432.CCR-21-3752
Published: 01 April 2022
View articletitled, Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Open the PDF for Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment in another window
Includes: Supplementary data
Journal Articles

Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

Available to Purchase
Hanneke van der Wijngaart, Louisa R. Hoes, J. Maxime van Berge Henegouwen, Daphne L. van der Velden, Laurien J. Zeverijn, Paul Roepman, Erik van Werkhoven, Wendy W.J. de Leng, Anne M.L. Jansen, Niven Mehra, Debbie G.J. Robbrecht, Mariette Labots, Derk Jan A. de Groot, Ann Hoeben, Paul Hamberg, Hans Gelderblom, Emile E. Voest, Henk M.W. Verheul
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6106–6114.
https://doi.org/10.1158/1078-0432.CCR-21-1104
Published: 15 November 2021
View articletitled, Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
Open the PDF for Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types in another window
Includes: Supplementary data
Journal Articles

FDG PET and FES PET Predict PFS on Endocrine Therapy—Letter

Free
Lemonitsa H. Mammatas, Erik J. van Helden, Henk M.W. Verheul, Catharina W. Menke-van der Houven van Oordt
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1): 248.
https://doi.org/10.1158/1078-0432.CCR-17-2380
Published: 02 January 2018
View articletitled, FDG PET and FES PET Predict PFS on Endocrine Therapy—Letter
Open the PDF for FDG PET and FES PET Predict PFS on Endocrine Therapy—Letter in another window
Journal Articles

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

Free
Laetitia E. Lamberts, Catharina W. Menke-van der Houven van Oordt, Eva J. ter Weele, Frederike Bensch, Michiel M. Smeenk, Johannes Voortman, Otto S. Hoekstra, Simon P. Williams, Bernard M. Fine, Daniel Maslyar, Johan R. de Jong, Jourik A. Gietema, Carolien P. Schröder, Alphons H.H. Bongaerts, Marjolijn N. Lub-de Hooge, Henk M.W. Verheul, Sandra M. Sanabria Bohorquez, Andor W.J.M. Glaudemans, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1642–1652.
https://doi.org/10.1158/1078-0432.CCR-15-1272
Published: 31 March 2016
View articletitled, ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment
Open the PDF for ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment in another window
Includes: Supplementary data
Journal Articles

Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer

Free
Annette A. van Zweeden, Hans J. van der Vliet, Johanna W. Wilmink, Martijn R. Meijerink, Otto W.M. Meijer, Anna M.E. Bruynzeel, Geertjan van Tienhoven, Elisa Giovannetti, Geert Kazemier, Maarten A.J.M. Jacobs, Henk M.W. Verheul
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (20): 4569–4575.
https://doi.org/10.1158/1078-0432.CCR-14-3364
Published: 14 October 2015
View articletitled, Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer
Open the PDF for Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

Free
Kristy J. Gotink, Henk J. Broxterman, Mariette Labots, Richard R. de Haas, Henk Dekker, Richard J. Honeywell, Michelle A. Rudek, Laurens V. Beerepoot, René J. Musters, Gerrit Jansen, Arjan W. Griffioen, Yehuda G. Assaraf, Roberto Pili, Godefridus J. Peters, Henk M.W. Verheul
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7337–7346.
https://doi.org/10.1158/1078-0432.CCR-11-1667
Published: 30 November 2011
View articletitled, Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
Open the PDF for Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance in another window
Includes: Supplementary data
Journal Articles

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

Free
Marlies H.G. Langenberg, Petronella O. Witteveen, Jeanine M. Roodhart, Henk M.W. Verheul, Marja Mergui-Roelvink, Jana van der Sar, Erich Brendel, Nicole Laferriere, Jan H.M. Schellens, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7): 2187–2197.
https://doi.org/10.1158/1078-0432.CCR-09-2436
Published: 31 March 2010
View articletitled, Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors
Open the PDF for Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors in another window
Journal Articles

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Free
Udai Banerji, D. Ross Camidge, Henk M.W. Verheul, Roshan Agarwal, Debashis Sarker, Stan B. Kaye, Ingrid M.E. Desar, Johanna N.H. Timmer-Bonte, S. Gail Eckhardt, Karl D. Lewis, Kathryn H. Brown, Mireille V. Cantarini, Clive Morris, Sarah M.A. George, Paul D. Smith, Carla M.L. van Herpen
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1613–1623.
https://doi.org/10.1158/1078-0432.CCR-09-2483
Published: 28 February 2010
View articletitled, The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
Open the PDF for The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

A Multiple-Loop, Double-Cube Microarray Design Applied to Prostate Cancer Cell Lines with Variable Sensitivity to Histone Deacetylase Inhibitors

Free
Madeleine S.Q. Kortenhorst, Marianna Zahurak, Shabana Shabbeer, Sushant Kachhap, Nathan Galloway, Giovanni Parmigiani, Henk M.W. Verheul, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 6886–6894.
https://doi.org/10.1158/1078-0432.CCR-08-0119
Published: 03 November 2008
View articletitled, A Multiple-Loop, Double-Cube Microarray Design Applied to Prostate Cancer Cell Lines with Variable Sensitivity to Histone Deacetylase Inhibitors
Open the PDF for A Multiple-Loop, Double-Cube Microarray Design Applied to Prostate Cancer Cell Lines with Variable Sensitivity to Histone Deacetylase Inhibitors in another window
Journal Articles

Combination Strategy Targeting the Hypoxia Inducible Factor-1α with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors

Free
Henk M.W. Verheul, Brenda Salumbides, Karen Van Erp, Hans Hammers, David Z. Qian, Tolib Sanni, Peter Atadja, Roberto Pili
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (11): 3589–3597.
https://doi.org/10.1158/1078-0432.CCR-07-4306
Published: 02 June 2008
View articletitled, Combination Strategy Targeting the Hypoxia Inducible Factor-1α with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors
Open the PDF for Combination Strategy Targeting the Hypoxia Inducible Factor-1α with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors in another window
Journal Articles

Platelets Take Up the Monoclonal Antibody Bevacizumab

Free
Henk M.W. Verheul, Martijn P.J. Lolkema, David Z. Qian, Yvonne H.A. Hilkes, Eleni Liapi, Jan-Willem N. Akkerman, Roberto Pili, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5341–5347.
https://doi.org/10.1158/1078-0432.CCR-07-0847
Published: 17 September 2007
View articletitled, Platelets Take Up the Monoclonal Antibody Bevacizumab
Open the PDF for Platelets Take Up the Monoclonal Antibody Bevacizumab in another window
Journal Articles

Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model

Free
Henk M.W. Verheul, Hans Hammers, Karen van Erp, Yonfeng Wei, Tolib Sanni, Brenda Salumbides, David Z. Qian, George D. Yancopoulos, Roberto Pili
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (14): 4201–4208.
https://doi.org/10.1158/1078-0432.CCR-06-2553
Published: 18 July 2007
View articletitled, Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model
Open the PDF for Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model in another window